Drugs / AZD3974
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07290283 | Dec 2025 → Oct 2026 expected | — | AstraZeneca | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD3974 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07290283 ↗ |
| Route | Oral | “AZD3974 will be administered as an oral solution.” NCT07290283 ↗ |